Correction to: Preliminary Results from the FOGSI's National Registry on Pregnancy with COVID-19

Gandhi, Alpesh; Ganatra, Atul; Tank, Parikshit

doi:10.1007/s13224-021-01570-2

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results indicate that gestational age at infection of SARS-CoV-2 plays a significant role in the pregnancy outcome. Women during their third trimester, specifically after 34 weeks of gestation, should practice social distancing and respiratory protection to reduce risk of adverse pregnancy outcomes [27] with an emphasis on PTB during 35-37 weeks of gestation. While no adverse outcomes were observed in women infected in the earlier trimesters, these parameters should not be regarded solely as reassurance for the impact of COVID-19 as they may not be sufficiently sensitive to reflect other potential differences in the mother or newborn [28].…”

Section: Plos Onementioning

confidence: 99%

Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study

et al. 2022

View full text Add to dashboard Cite

Objectives Data regarding women infected with SARS-CoV-2 during early trimesters are scarce. We aimed to assess preterm birth (PTB) and small-for-gestational-age (SGA) rates in a large and unselected cohort by trimester at infection and overall. Design A retrospective cohort study including all women with a positive SARS-CoV-2 RT-PCR test during a non-ectopic singleton pregnancy between February 21st 2020 and July 2nd 2021 (N = 2753). Each infected woman was matched to a non-infected pregnant woman by age, last menstruation date, sector, and socioeconomic status. Methods Logistic regression was conducted to assess the risks of PTB and SGA including an interaction between group and trimester of infection. Multivariable models included underlying diseases, previous abortions and null parity. Subgroup analyses were conducted on symptomatic infected women and matched non-infected women. Results A total of 2753 /2789 (98.7%) eligible women that were infected during pregnancy could be matched, among them, 17.4% and 48.4% were infected during the first and third trimesters, respectively. While first and second trimester infections were not associated with PTB (p>0.8), third trimester infections and in particular after 34 weeks of gestation had a greater risk of PTB with adjusted ORs of 2.76 (95% CI 1.63–4.67) and 7.10 (95% CI 2.44–20.61), respectively. PTB risk was further heightened in symptomatic third trimester infections (OR = 4.28, 95% CI 1.94–9.25). SGA risk was comparable between study groups across all trimesters of infection. Pregnancy loss incidence was similar in both groups (adjusted OR = 1.16; 95% CI 0.90–1.50). Conclusion SARS-CoV-2 infection was associated with increased risk of PTB only among women infected during late pregnancy, particularly among symptomatic women.

show abstract

Section: Plos Onementioning

confidence: 99%

Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Only approximately 1 to 3% of neonates born to mothers with COVID-19 have a positive SARS-CoV-2 RT-PCR in neonatal period. 10 43 66 76 The risk of neonatal infection is much lower when positive maternal test and associated symptoms were over 14 days before delivery. 66 77 78 While much attention is given to the small percentage of SARS-CoV-2-positive neonates born to mothers with COVID-19 as evidenced by a positive RT-PCR, it is suspected that a significant number of infants with a negative test for SARS-CoV-2 may have been affected due to downstream effects of maternal illness.…”

Section: Outcomes Of Infants Born To Mothers With Covid-19mentioning

confidence: 99%

Mother to Newborn Transmission of SARS-CoV-2 Infection: Evolution of Evidence in 1.5 Years of COVID-19 Pandemic

Gupta

Kamity²,

Sharma

et al. 2022

Am J Perinatol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic caused significant mortality and morbidity in people of all age groups worldwide. Given the uncertainty regarding the mode of transmission and potential effects of COVID-19 on pregnant mothers and their newborns, guidelines for taking care of maternal–newborn dyads have evolved tremendously since the pandemic began. There has been an enormous influx of published materials regarding the outcomes of mothers and newborns. Still, multiple knowledge gaps regarding comprehensive information about risk to the mothers and newborns exist, which need to be addressed. Current evidence suggests that mothers with symptomatic COVID-19 infection are at increased risk of severe illness during pregnancy, with a higher need for respiratory support and premature deliveries. Neonates born to mothers with COVID-19 are at increased risk of needing intensive care; however, most newborns do well after birth. As new mutant variants arise, we need to be cautious while proactively understanding any new evolving patterns. All leading health authorities strongly recommend COVID-19 vaccination before or during pregnancy to reduce the risk of maternal morbidities and benefit from passing antibodies to newborns prenatally and via breastmilk. Additionally, there are racial, ethnic, and socioeconomic disparities in outcomes and vaccination coverage for pregnant women. This article summarizes the rapidly evolving evidence for the last 1.5 years and aims to help health care professionals care for mothers with COVID-19 and their newborns. Key Points

show abstract

Correction to: Preliminary Results from the FOGSI's National Registry on Pregnancy with COVID-19

Cited by 2 publications

References 0 publications

Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study

Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study

Mother to Newborn Transmission of SARS-CoV-2 Infection: Evolution of Evidence in 1.5 Years of COVID-19 Pandemic

Contact Info

Product

Resources

About